Literature DB >> 7989112

The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival.

B R Dix1, P Robbins, R Soong, D Jenner, A K House, B J Iacopetta.   

Abstract

Our study was undertaken to determine the prognostic significance of several common genetic alterations observed in colorectal carcinomas. We have previously analysed loss of heterozygosity of the MCC, APC, p53 and DCC tumour suppressor gene loci as well as p53 gene mutations and protein over-expression in a series of 100 Dukes' stage B and C colorectal tumours obtained at surgery. To extend our observations of alterations that may occur in these tumours, mutations to the c-Ki-ras oncogene and APC tumour suppressor gene were detected by PCR single-strand conformation polymorphism analysis. Short-term follow-up revealed no significant association between overall patient survival and any single, or combination of, genetic alteration(s). Surprisingly, patients whose tumours showed evidence of p53 protein over-expression/accumulation by immunocytochemistry (ICC) had a significantly better prognosis (p = 0.039) than those whose tumours had no p53 ICC reactivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989112     DOI: 10.1002/ijc.2910590606

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

Review 2.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

3.  KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.

Authors:  Neelesh Sharma; Maher Saifo; Ila R Tamaskar; Ramkumar Bhuvaneswari; Terry Mashtare; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  K-ras mutations in patients with early colorectal cancers.

Authors:  H J Andreyev; J V Tilsed; D Cunningham; S A Sampson; A R Norman; H J Schneider; P A Clarke
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

5.  Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer.

Authors:  W S Samowitz; J A Holden; K Curtin; S L Edwards; A R Walker; H A Lin; M A Robertson; M F Nichols; K M Gruenthal; B J Lynch; M F Leppert; M L Slattery
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.

Authors:  Petra Minarikova; Lucie Benesova; Tereza Halkova; Barbora Belsanova; Stepan Suchanek; Jiri Cyrany; Inna Tuckova; Jan Bures; Miroslav Zavoral; Marek Minarik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

7.  Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?

Authors:  Nazım Emrah Koçer; Fazilet Kayaselçuk
Journal:  Target Oncol       Date:  2013-04-16       Impact factor: 4.493

8.  Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

Authors:  Zuo Yunxia; Cao Jun; Zhu Guanshan; Lu Yachao; Zhou Xueke; Li Jin
Journal:  BMC Med Genet       Date:  2010-02-26       Impact factor: 2.103

Review 9.  Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Authors:  Hui-Yan Luo; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

10.  Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.

Authors:  A Syed Sameer; Shakeel ul Rehman; Arshad A Pandith; Nidda Syeed; Zaffar A Shah; Nissar A Chowdhri; Khursheed A Wani; Mushtaq A Siddiqi
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.